May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

(iVillage Total Health) - Men who undergo androgen deprivation therapy to treat prostate cancer may be a greater risk of developing gum disease, a new study concluded. The prostate is a walnut-size ...

The average age of men who get diagnosed is 67.

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Hormone-suppressing drugs, increasingly used to treat prostate cancer, make men so prone to broken bones that the risks of the treatment may outweigh the benefits in those whose cancer was caught ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

NHS staff are going on tour to raise awareness of prostate cancer. The Humber and North Yorkshire Cancer Alliance (HNYCA) is ...